## Blockade of Nicotine Self-Administration with Nicotinio

Pharmacology Biochemistry and Behavior 62, 743-751 DOI: 10.1016/s0091-3057(98)00226-3

**Citation Report** 

#	Article	IF	Citations
1	Nornicotine is self-administered intravenously by rats. Psychopharmacology, 1999, 146, 290-296.	1.5	109
2	Involvement of Nicotinic Receptors in Alcohol Self-Administration. Alcoholism: Clinical and Experimental Research, 2000, 24, 155-163.	1.4	189
3	Effects of methyllycaconitine (MLA), an α 7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology, 2000, 149, 388-396.	1.5	87
4	Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology, 2000, 151, 392-405.	1.5	242
5	Antagonism of stimulus properties of nicotine by dihydro-β-erythroidine (DHβE) in rats. Psychopharmacology, 2000, 149, 140-146.	1.5	48
6	Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine and Tobacco Research, 2000, 2, 19-37.	1.4	342
7	Behavioural Pharmacology and Neurobiology of Nicotine Reward and Dependence. Handbook of Experimental Pharmacology, 2000, , 603-750.	0.9	23
8	The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience, 2000, 96, 735-742.	1.1	104
9	Novel therapy for COPD. Expert Opinion on Investigational Drugs, 2000, 9, 3-23.	1.9	15
10	Mecamylamine: new therapeutic uses and toxicity/risk profile. Clinical Therapeutics, 2001, 23, 532-565.	1.1	87
11	GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology, 2001, 158, 190-197.	1.5	92
12	Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacology Biochemistry and Behavior, 2001, 68, 187-197.	1.3	63
13	A study of the nicotinic agonist SIB-1553A on locomotion, and attention as measured by the five-choice serial reaction time task. Pharmacology Biochemistry and Behavior, 2001, 70, 505-513.	1.3	26
14	Antagonism of the anxiolytic effect of nicotine in the dorsal raphé nucleus by dihydro-β-erythroidine. Pharmacology Biochemistry and Behavior, 2001, 70, 491-496.	1.3	42
15	Neurobiology of the nicotine withdrawal syndrome. Pharmacology Biochemistry and Behavior, 2001, 70, 531-549.	1.3	267
16	Cue dependency of nicotine self-administration and smoking. Pharmacology Biochemistry and Behavior, 2001, 70, 515-530.	1.3	388
17	Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 664-672.	1.3	64
18	Nicotine Self-Administration in Animals: A Reevaluation. Addiction Research and Theory, 2002, 10, 545-579.	1.2	16

ARTICLE IF CITATIONS # The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste 19 2.0 112 aversion. Neuropharmacology, 2002, 42, 530-539. Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3Î<sup>2</sup>4 1.7 90 nicotinic receptors. European Journal of Pharmacológy, 2002, 448, 185-191. Rat strain differences in nicotine self-administration using an unlimited access paradigm. Brain 21 79 1.1 Research, 2002, 930, 12-20. Nicotine potentiation of brain stimulation reward reversed by DHÎ<sup>2</sup>E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology, 2002, 160, 56-66. Effects of Nicotine on Alcohol Consumption. Alcoholism: Clinical and Experimental Research, 2002, 23 1.4 24 26, 1915-1916. Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotoxicity Research, 2002, 4, 297-313. 1.3 Investigating the actions of bupropion on dependence-related effects of nicotine in rats. 25 1.5 79 Psychopharmacology, 2003, 165, 405-412. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology, 2003, 169, 1-9. 1.5 26 Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine 27 1.7 31 self-administration. European Journal of Pharmacology, 2003, 472, 99-110. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with 1.3 morphine. Pharmacology Biochemistry and Behavior, 2003, 74, 803-810. Bitonic dose–response functions for reinforcing and self-reported effects of nitrous oxide in 29 1.3 10 humans. Pharmacology Biochemistry and Behavior, 2003, 74, 851-857. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in 0.6 135 rats. Synapse, 2003, 50, 20-28. Place Preference Test in Rodents., 2003, Chapter 10, Unit 10.4.  $\mathbf{31}$ 6 Place Preference Test in Rodents. Current Protocols in Neuroscience, 2003, 22, Unit 9.15. 2.6 Advances in the management of chronic obstructive pulmonary disease. Expert Opinion on 33 0.9 3 Pharmacotherapy, 2003, 4, 1063-1082. SSR591813, a Novel Selective and Partial  $\hat{I} \pm 4\hat{I}^2$  Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 407-420. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and 35 2.0 58 d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology, 2004, 18, 534-543. Effect of SCH 23390 on (±)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in 1.3 rats. Pharmacology Biochemistry and Behavior, 2004, 77, 745-750.

#	Article	IF	CITATIONS
37	Role of Î <sup>3</sup> -Aminobutyric Acid (GABA) and Metabotropic Glutamate Receptors in Nicotine Reinforcement: Potential Pharmacotherapies for Smoking Cessation. Annals of the New York Academy of Sciences, 2004, 1025, 491-503.	1.8	57
38	The GABA B receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology, 2004, 172, 179-186.	1.5	123
39	Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology, 2004, 173, 64-72.	1.5	82
40	Modulation of CREB expression and phosphorylation in the rat nucleus accumbens during nicotine exposure and withdrawal. Journal of Neuroscience Research, 2004, 77, 884-891.	1.3	37
41	Neurochemical and behavioral studies on ethanol and nicotine interactions. Neuroscience and Biobehavioral Reviews, 2004, 27, 713-720.	2.9	197
42	Adaptations in cholinergic transmission in the ventral tegmental area associated with the affective signs of nicotine withdrawal in rats. Neuropharmacology, 2004, 47, 572-579.	2.0	60
43	Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology, 2004, 18, 534-543.	2.0	68
44	CB receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry and Behavior, 2005, 81, 387-395.	1.3	124
45	Wistar Kyoto rats exhibit reduced sucrose pellet reinforcement behavior and intravenous nicotine self-administration. Pharmacology Biochemistry and Behavior, 2005, 82, 330-337.	1.3	23
46	The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology, 2005, 179, 255-261.	1.5	150
47	In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (â~)-cytisine. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2974-2979.	1.0	67
48	3,5-Bicyclic aryl piperidines: A novel class of $\hat{1}\pm4\hat{1}^22$ neuronal nicotinic receptor partial agonists for smoking cessation. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4889-4897.	1.0	69
49	Tolerance does not develop to the decrease in nicotine selfâ $\in$ administration produced by repeated bupropion administration. Nicotine and Tobacco Research, 2005, 7, 901-907.	1.4	32
50	Acetaldehyde Enhances Acquisition of Nicotine Self-Administration in Adolescent Rats. Neuropsychopharmacology, 2005, 30, 705-712.	2.8	215
51	Repeated Administration of the GABAB Receptor Agonist CGP44532 Decreased Nicotine Self-Administration, and Acute Administration Decreased Cue-Induced Reinstatement of Nicotine-Seeking in Rats. Neuropsychopharmacology, 2005, 30, 119-128.	2.8	100
52	Smoking Cessation: Techniques and Potential Benefits. Thoracic Surgery Clinics, 2005, 15, 189-194.	0.4	4
53	The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research Reviews, 2005, 49, 505-528.	9.1	109
54	Varenicline:  An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation. Journal of Medicinal Chemistry, 2005, 48, 3474-3477.	2.9	878

ARTICLE IF CITATIONS Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use 4.0 217 55 Cessation Agent. CNS Neuroscience & Therapeutics, 2006, 12, 178-207. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of 789 abuse?. Neuroscience and Biobehavioral Reviews, 2006, 30, 215-238. Reinstatement of nicotine-seeking behavior by drug-associated stimuli after extinction in rats. 58 1.5 59 Psychopharmacology, 2006, 184, 417-425. Effect of a novel nicotinic receptor antagonist, N,Nâ€2-dodecane-1,12-diyl-bis-3-picolinium dibromide, on 59 nicotine self-administration and hyperactivity in rats. Psychopharmacology, 2006, 184, 426-434. The Î<sup>2</sup>2 but not α7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned 60 1.5 184 place preference in mice. Psychopharmacology, 2006, 184, 339-344. Ligands selective for  $\hat{l}\pm4\hat{l}^22$  but not  $\hat{l}\pm3\hat{l}^24$  or  $\hat{l}\pm7$  nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology, 2006, 190, 157-170. 1.5 Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the 62 discriminative stimulus effects of nicotine in rats. European Journal of Pharmacology, 2006, 540, 1.7 46 96-106. Withdrawal from chronic nicotine in adolescent and adult rats. Pharmacology Biochemistry and 1.3 60 Behavior, 2006, 85, 648-657. Extended Access to Nicotine Self-Administration Leads to Dependence: Circadian Measures. Withdrawal Measures, and Extinction Behavior in Rats. Journal of Pharmacology and Experimental 1.3 64 116 Therapeutics, 2007, 320, 180-193. Mecamylamine Attenuates Cue-Induced Reinstatement of Nicotine-Seeking Behavior in Rats. 2.8 Neuropsychopharmacology, 2007, 32, 710-718. Antagonism of CRF Receptors Prevents the Deficit in Brain Reward Function Associated with 99 66 2.8 Precipitated Nicotine Withdrawal in Rats. Neuropsychopharmacology, 2007, 32, 955-963. Motivational effects of nicotine as measured in a runway model of drug self-administration. 0.8 Behavioural Pharmacology, 2007, 18, 265-271. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide 68 (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus 2.0 42 accumbens. Neuropharmacology, 2007, 52, 755-763. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology, 2007, 52, 1415-1425. 59 Effects of the CRF receptor antagonist d-Phe CRF( $12\hat{a} \in 41$ ) and the  $\hat{l} \pm 2$ -adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology, 70 2.0 101 2007, 53, 958-966. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. European 203 Neuropsychopharmacology, 2007, 17, 145-155. Translational research in medication development for nicotine dependence. Nature Reviews Drug 72 21.5 142 Discovery, 2007, 6, 746-762. Varenicline: progress in smoking cessation treatment. Expert Opinion on Pharmacotherapy, 2007, 8, 1757-1767.

#	Article	IF	CITATIONS
74	Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. European Journal of Pharmacology, 2007, 554, 164-174.	1.7	67
75	â€~Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. Pharmacology Biochemistry and Behavior, 2007, 86, 346-353.	1.3	61
76	Periadolescent nicotine exposure produces sensitization to reinforcement by diazepam in the rat. Neurotoxicology and Teratology, 2007, 29, 31-36.	1.2	11
77	Adolescent vs. adult-onset nicotine self-administration in male rats: Duration of effect and differential nicotinic receptor correlates. Neurotoxicology and Teratology, 2007, 29, 458-465.	1.2	127
78	Guidelines on nicotine dose selection for in vivo research. Psychopharmacology, 2007, 190, 269-319.	1.5	694
79	Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology, 2007, 194, 463-473.	1.5	64
80	Age differences in the spontaneous acquisition of nicotine self-administration in male Wistar and Long–Evans rats. Psychopharmacology, 2008, 197, 45-58.	1.5	38
81	Nicotine analog inhibition of nicotine self-administration in rats. Psychopharmacology, 2008, 199, 605-613.	1.5	7
82	Smoking Cessation: Significance and Implications for Children. Clinical Reviews in Allergy and Immunology, 2008, 34, 231-249.	2.9	3
83	Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats. Synapse, 2008, 62, 935-939.	0.6	30
84	The neurocircuitry of addiction: an overview. British Journal of Pharmacology, 2008, 154, 261-274.	2.7	333
85	Serotonin receptors as potential targets for modulation of nicotine use and dependence. Progress in Brain Research, 2008, 172, 361-383.	0.9	50
86	<i>N,N</i> ′-Alkane-diyl- <i>bis</i> -3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-Evoked Dopamine Release and Hyperactivity. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 563-576.	1.3	37
87	Nicotine Self-Administration, Extinction Responding and Reinstatement in Adolescent and Adult Male Rats: Evidence Against a Biological Vulnerability to Nicotine Addiction during Adolescence. Neuropsychopharmacology, 2008, 33, 739-748.	2.8	95
88	Methylphenidate Enhances the Abuse-Related Behavioral Effects of Nicotine in Rats: Intravenous Self-Administration, Drug Discrimination, and Locomotor Cross-Sensitization. Neuropsychopharmacology, 2008, 33, 1137-1148.	2.8	41
89	Positive Modulation of GABA <sub>B</sub> Receptors Decreased Nicotine Self-Administration and Counteracted Nicotine-Induced Enhancement of Brain Reward Function in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 306-314.	1.3	84
90	Motivational Effects of Methamphetamine as Measured by the Runway Method Using Priming Stimulation of Intracranial Self-stimulation Behavior. Biological and Pharmaceutical Bulletin, 2008, 31, 541-545.	0.6	7
91	Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behavioural Pharmacology, 2008, 19, 461-484.	0.8	123

#	Article	IF	CITATIONS
92	Contribution of Animal Models and Preclinical Human Studies to Medication Development for Nicotine Dependence. , 2008, , 179-219.		4
93	Corticotropin-Releasing Factor Within the Central Nucleus of the Amygdala and the Nucleus Accumbens Shell Mediates the Negative Affective State of Nicotine Withdrawal in Rats. Neuropsychopharmacology, 2009, 34, 1743-1752.	2.8	79
94	Rats Self-Administer Intravenous Nicotine Delivered in a Novel Smoking-Relevant Procedure: Effects of Dopamine Antagonists. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 633-640.	1.3	60
95	Nicotinic Receptor Activation Increases [ <sup>3</sup> H]Dopamine Uptake and Cell Surface Expression of Dopamine Transporters in Rat Prefrontal Cortex. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 931-939.	1.3	20
96	Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacology Biochemistry and Behavior, 2009, 91, 461-467.	1.3	71
97	Effects of mecamylamine on nicotine-induced conditioned hyperactivity and sensitization in differentially reared rats. Pharmacology Biochemistry and Behavior, 2009, 93, 59-66.	1.3	24
98	Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed- and progressive-ratio schedules of reinforcement. Psychopharmacology, 2009, 201, 557-568.	1.5	20
99	Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology, 2009, 203, 99-108.	1.5	79
100	Anxiolytic effects of nicotine in a rodent test of approach–avoidance conflict. Psychopharmacology, 2009, 204, 541-549.	1.5	33
101	Correlates of individual differences in compensatory nicotine self-administration in rats following a decrease in nicotine unit dose. Psychopharmacology, 2009, 205, 599-611.	1.5	15
102	Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacologica Sinica, 2009, 30, 723-739.	2.8	35
103	Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nature Reviews Drug Discovery, 2009, 8, 733-750.	21.5	591
104	Neurobiological mechanisms contributing to alcohol–stress–anxiety interactions. Alcohol, 2009, 43, 509-519.	0.8	72
105	Chapter 4 Case History: Chantixâ"¢/Champixâ"¢ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid. Annual Reports in Medicinal Chemistry, 2009, , 71-101.	0.5	16
106	Bupropion attenuates methamphetamine self-administration in adult male rats. Drug and Alcohol Dependence, 2009, 100, 54-62.	1.6	37
107	Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of α4β2 nicotinic receptors in rats. Neuropharmacology, 2009, 57, 60-66.	2.0	52
108	The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. Behavioural Pharmacology, 2009, 20, 211-225.	0.8	26
109	Nicotine and cocaine self-administration using a multiple schedule of intravenous drug and sucrose reinforcement in rats. Behavioural Pharmacology, 2010, 21, 182-193.	0.8	15

#	Article	IF	CITATIONS
110	Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 361-370.	1.4	56
111	Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology, 2010, 208, 143-158.	1.5	68
112	Patterns of responding differentiate intravenous nicotine self-administration from responding for a visual stimulus in C57BL/6J mice. Psychopharmacology, 2010, 212, 283-299.	1.5	26
113	Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacology Biochemistry and Behavior, 2010, 96, 141-147.	1.3	24
114	Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug, Healthcare and Patient Safety, 2010, 2010, 39.	1.0	19
115	Review: Nicotinic receptors and stages of nicotine dependence. Journal of Psychopharmacology, 2010, 24, 793-808.	2.0	17
116	Nicotine reduction revisited: science and future directions. Tobacco Control, 2010, 19, e1-e1.	1.8	90
118	The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1455-1464.	2.5	28
119	Structure–Activity Relationship Studies of Sulfonylpiperazine Analogues as Novel Negative Allosteric Modulators of Human Neuronal Nicotinic Receptors. Journal of Medicinal Chemistry, 2011, 54, 8681-8692.	2.9	24
120	Stimulation of α2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology, 2011, 60, 303-311.	2.0	69
121	Intravenous nicotine self-administration and cue-induced reinstatement in mice: Effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology, 2011, 61, 687-698.	2.0	76
122	bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 2011, 163, 346-357.	2.7	25
123	Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochemical Pharmacology, 2011, 82, 984-995.	2.0	116
124	A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology, 2011, 217, 153-166.	1.5	41
125	Patterns of Nicotinic Receptor Antagonism: Nicotine Discrimination Studies. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 194-202.	1.3	50
126	Â4Â2 Nicotinic Acetylcholine Receptors on Dopaminergic Neurons Mediate Nicotine Reward and Anxiety Relief. Journal of Neuroscience, 2011, 31, 10891-10902.	1.7	124
127	The Metabotropic Glutamate 2/3 Receptor Agonist LY379268 Blocked Nicotine-Induced Increases in Nucleus Accumbens Shell Dopamine only in the Presence of a Nicotine-Associated Context in Rats. Neuropsychopharmacology, 2011, 36, 2111-2124.	2.8	27
128	Impact of Tobacco Regulation on Animal Research: New Perspectives and Opportunities. Nicotine and Tobacco Research, 2012, 14, 1319-1338.	1.4	39

#	Article	IF	CITATIONS
129	Defining the Putative Inhibitory Site for a Selective Negative Allosteric Modulator of Human α4β2 Neuronal Nicotinic Receptors. ACS Chemical Neuroscience, 2012, 3, 682-692.	1.7	12
130	Nicotine-taking and nicotine-seeking in C57Bl/6J mice without prior operant training or food restriction. Behavioural Brain Research, 2012, 230, 34-39.	1.2	9
131	A new criterion for acquisition of nicotine self-administration in rats. Drug and Alcohol Dependence, 2012, 124, 63-69.	1.6	15
132	Galantamine, an Acetylcholinesterase Inhibitor and Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors, Attenuates Nicotine Taking and Seeking in Rats. Neuropsychopharmacology, 2012, 37, 2310-2321.	2.8	56
133	The reinforcement threshold for nicotine as a target for tobacco control. Drug and Alcohol Dependence, 2012, 125, 1-7.	1.6	32
134	Psychiatric Disorders. Methods in Molecular Biology, 2012, , .	0.4	3
135	AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats. Neuropsychopharmacology, 2012, 37, 1367-1376.	2.8	69
136	Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice. Psychopharmacology, 2012, 223, 159-168.	1.5	20
137	Stress and addiction: contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. Frontiers in Molecular Neuroscience, 2012, 5, 91.	1.4	48
138	The "Stop" and "Go" of Nicotine Dependence: Role of GABA and Glutamate. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a012146-a012146.	2.9	48
139	Nicotineâ€motivated behavior in <i><scp>C</scp>aenorhabditis elegans</i> requires the nicotinic acetylcholine receptor subunits <i>acrâ€5</i> and <i>acrâ€15</i> . European Journal of Neuroscience, 2013, 37, 743-756.	1.2	24
140	Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine. Neuropharmacology, 2013, 75, 138-144.	2.0	24
141	Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats. Drug and Alcohol Dependence, 2013, 131, 284-297.	1.6	23
142	<scp>CC</scp> 4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 <scp>nAChR</scp> with improved selectivity for tobacco smoking cessation. British Journal of Pharmacology, 2013, 168, 835-849.	2.7	31
143	Scaffold Ranking and Positional Scanning Utilized in the Discovery of nAChR-Selective Compounds Suitable for Optimization Studies. Journal of Medicinal Chemistry, 2013, 56, 10103-10117.	2.9	32
144	Erythrina mulungu Alkaloids Are Potent Inhibitors of Neuronal Nicotinic Receptor Currents in Mammalian Cells. PLoS ONE, 2013, 8, e82726.	1.1	31
145	Animal Models of Nicotine Exposure: Relevance to Second-Hand Smoking, Electronic Cigarette Use, and Compulsive Smoking. Frontiers in Psychiatry, 2013, 4, 41.	1.3	53
146	Effects of blockade of α4β2 and α7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats. International Journal of Neuropsychopharmacology, 2014, 17, 105-116.	1.0	25

ARTICLE IF CITATIONS The effects of nicotine and tobacco particulate matter on dopamine uptake in the rat brain. Synapse, 0.6 26 147 2014, 68, 45-60. Design and synthesis of αâ€conotoxin GID analogues as selective α4Î<sup>2</sup>2 nicotinic acetylcholine receptor 148 1.2 antagonists. Biopolymers, 2014, 102, 78-87. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the 149 1.2 11 reinstatement of nicotine-seeking behavior in rats. Behavioural Brain Research, 2014, 274, 168-175. Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. 0.9 Journal of General Physiology, 2014, 143, 51-66. Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models. 151 2.7 46 British Journal of Pharmacology, 2014, 171, 4729-4766. Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology, 2014, 76, 533-544. Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine 153 1.3 52 in male rodents.. Experimental and Clinical Psychopharmacology, 2014, 22, 9-22. <scp>AT</scp>â€1001: a highâ€affinity α3β4 <scp>nAChR</scp> ligand with novel nicotineâ€suppressive 154 2.7 pharmacology. British Journal of Pharmacology, 2015, 172, 1834-1845. Acute Nicotine Administration Increases BOLD fMRI Signal in Brain Regions Involved in Reward 155 Signaling and Compulsive Drug Intake in Rats. International Journal of Neuropsychopharmacology, 30 1.0 2015, 18, pyu011-pyu011. Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a 1.6 rodent model of nicotine reduction policy. Drug and Alcohol Dependence, 2015, 151, 181-193. The effect of varenicline on the development and expression of nicotineâ€induced behavioral 157 1.4 13 sensitization and crossâ€sensitization in rats. Addiction Biology, 2015, 20, 248-258. Effects of environmental enrichment on <scp>ERK</scp>1/2 phosphorylation in the rat prefrontal cortex following nicotineâ€induced sensitization or nicotine selfâ€administration. European Journal of 1.2 158 Neuroscience, 2015, 41, 109-119. 159 Effects of Environmental Enrichment on Nicotine Addiction., 2016, 246-253. 0 Characterization of Cue-Induced Reinstatement of Nicotine-Seeking Behavior in Smoking Relapse., 2016, ,237-245. Enhancing effect of menthol on nicotine self-administration in rats. Psychopharmacology, 2016, 233, 161 1.5 61 3417-3427. Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology, 2017, 234, 29 1419-1437. Highly Selective and Potent  $\hat{I}$  +  $\hat{I}^2$  2 nAChR Antagonist Inhibits Nicotine Self-Administration and 163 2.9 9 Reinstatement in Rats. Journal of Medicinal Chemistry, 2017, 60, 10092-10104. Biodistribution and Radiation Dosimetry of <sup>11</sup>C-Nicotine from Whole-Body PET Imaging in 164 2.8 Humans. Journal of Nuclear Medicine, 2017, 58, 473-478.

#	Article	IF	CITATIONS
165	Overview of Nicotine Withdrawal and Negative Reinforcement (Preclinical). , 2017, , 1-20.		3
166	The nicotinic receptor drug sazetidine-A reduces alcohol consumption in mice without affecting concurrent nicotine consumption. Neuropharmacology, 2018, 133, 63-74.	2.0	13
167	Discovery and development of varenicline for smoking cessation. Expert Opinion on Drug Discovery, 2018, 13, 671-683.	2.5	65
168	Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats. Pain, 2018, 159, 2179-2191.	2.0	15
169	Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 397-409.	1.3	8
170	Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism. Neuropharmacology, 2018, 137, 286-296.	2.0	10
171	Genetic correlations between nicotine reinforcementâ€related behaviors and propensity toward high or low alcohol preference in two replicate mouse lines. Genes, Brain and Behavior, 2019, 18, e12515.	1.1	5
172	Dopamine receptor antagonists effects on low-dimensional attractors of local field potentials in optogenetic mice. PLoS ONE, 2019, 14, e0223469.	1.1	1
173	Nicotine Addiction and Alpha4beta2* Nicotinic Acetylcholine Receptors. , 2019, , 243-250.		0
174	The neurobiology of impulsivity and substance use disorders: implications for treatment. Annals of the New York Academy of Sciences, 2019, 1451, 71-91.	1.8	114
175	Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphineâ€conditioned place preference and associated changes in AMPA receptor binding. Addiction Biology, 2019, 24, 590-603.	1.4	28
176	Relationship Between Nicotine Intake and Reward Function in Rats With Intermittent Short Versus Long Access to Nicotine. Nicotine and Tobacco Research, 2020, 22, 213-223.	1.4	10
177	Shifting Frontiers in Basic Research on Nicotine and Tobacco Products. Nicotine and Tobacco Research, 2020, 22, 145-146.	1.4	0
178	Evaluation of Sex Differences in the Elasticity of Demand for Nicotine and Food in Rats. Nicotine and Tobacco Research, 2020, 22, 925-934.	1.4	13
179	Nicotine e-cigarette vapor inhalation effects on nicotine & cotinine plasma levels and somatic withdrawal signs in adult male Wistar rats. Psychopharmacology, 2020, 237, 613-625.	1.5	39
180	Nicotinic Receptors Underlying Nicotine Dependence: Evidence from Transgenic Mouse Models. Current Topics in Behavioral Neurosciences, 2020, 45, 101-121.	0.8	7
181	Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. Neuropharmacology, 2020, 178, 108225.	2.0	9
182	The Impact of Electronic Nicotine Delivery System (ENDS) Flavors on Nicotinic Acetylcholine Receptors and Nicotine Addiction-Related Behaviors. Molecules, 2020, 25, 4223.	1.7	16

#	Article	IF	CITATIONS
183	5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence. Progress in Brain Research, 2021, 259, 229-263.	0.9	3
184	Rewarding Effects of Nicotine Self-administration Increase Over Time in Male and Female Rats. Nicotine and Tobacco Research, 2021, 23, 2117-2126.	1.4	12
186	Nicotine-like discriminative and aversive effects of two α4β2-selective nicotine agonists, ispronicline and metanicotine. Behavioural Pharmacology, 2021, 32, 497-504.	0.8	1
187	Multiple Motivational Forces Contribute to Nicotine Dependence. Nebraska Symposium on Motivation, 2008, 55, 65-89.	0.9	15
188	Modeling Nicotine Addiction in Rats. Methods in Molecular Biology, 2012, 829, 243-256.	0.4	30
189	Biochemical and Physiological Processes in Brain Function and Drug Actions. Handbook of Experimental Pharmacology, 2004, , 3-33.	0.9	1
191	Accumbens Cholinergic Interneurons Mediate Cue-Induced Nicotine Seeking and Associated Glutamatergic Plasticity. ENeuro, 2021, 8, ENEURO.0276-20.2020.	0.9	11
192	Partial nicotinic acetylcholine (α4β2) agonists as promising new medications for smoking cessation. Indian Journal of Pharmacology, 2008, 40, 191.	0.4	3
194	Animal Models of Nicotine Addiction. , 2006, , 39-60.		0
195	Nicotine Self-Administration. Neuromethods, 2011, , 101-132.	0.2	1
197	Agents for Treatment of Withdrawal and Dependency: Varenicline. , 2020, , 1-32.		0
198	Targeting the 42- and 7-Subtypes of Nicotinic Acetylcholine Receptors for Smoking Cessation Medication Development. Journal of Addiction Research & Therapy, 2019, 10, .	0.2	5
199	Nanoscale Sub-Compartmentalization of the Dendritic Spine Compartment. Biomolecules, 2021, 11, 1697.	1.8	6
200	Neurobiological Mechanisms of Nicotine Reward and Aversion. Pharmacological Reviews, 2022, 74, 271-310.	7.1	36
201	Evaluation of motivational effects induced by intracranial self-stimulation behavior. Acta Medica Okayama, 2010, 64, 267-75.	0.1	6
203	The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats. European Journal of Pharmacology, 2022, 928, 175088.	1.7	4
204	Agents for Treatment of Withdrawal and Dependency: Varenicline. , 2022, , 2603-2633.		0
205	What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders. Journal of Medicinal Chemistry, 2023, 66, 107-121.	2.9	7

#	Article	IF	CITATIONS
206	Development of Dependence in Smokers and Rodents With Voluntary Nicotine Intake: Similarities and Differences. Nicotine and Tobacco Research, 2023, 25, 1229-1240.	1.4	3
207	The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats. Journal of Psychopharmacology, 2023, 37, 216-228.	2.0	3